<div id="readability-page-1"><p>Ionis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 157 million compared to USD 134 million a year ago. Net loss was USD 129 million compared to USD 140 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.95 a year ago. Diluted loss per share from continuing operations was USD 0.8 compared to USD 0.95 a year ago.<br/> For the nine months, revenue was USD 740 million compared to USD 479 million a year ago. Net loss was USD 152 million compared to USD 350 million a year ago. Basic loss per share from continuing operations was USD 0.95 compared to USD 2.38 a year ago. Diluted loss per share from continuing operations was USD 0.95 compared to USD 2.38 a year ago.</p></div>

Ionis制藥

<p>Ionis 製藥公司報告了 2025 年第三季度及前九個月的財務業績。第三季度收入同比增長至 1.57 億美元，較去年同期的 1.34 億美元有所增加，淨虧損為 1.29 億美元，較去年同期的 1.4 億美元有所改善。在前九個月，收入從 4.79 億美元上升至 7.4 億美元，淨虧損為 1.52 億美元，較 3.5 億美元有所減少。來自持續經營的基本和稀釋每股虧損分別改善至 0.8 美元和 0.95 美元，而去年同期為 0.95 美元和 2.38 美元</p>

Ionis 製藥公司公佈了截至2025年9月30日的第三季度和九個月的財務業績